{
    "organizations": [],
    "uuid": "1fd362757fce73714eea041232731be07be447eb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-seattle-genetics-says-fda-grants-i/brief-seattle-genetics-says-fda-grants-its-hodgkin-lymphoma-treatment-priority-review-status-idUSASB0BZEU",
    "ord_in_thread": 0,
    "title": "BRIEF-Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 2, 2018 / 1:11 PM / in 10 minutes BRIEF-Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status Reuters Staff 1 Min Read \nJan 2 (Reuters) - Seattle Genetics Inc: \n* FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR ADCETRISÂ® (BRENTUXIMAB VEDOTIN) IN FRONTLINE ADVANCED HODGKIN LYMPHOMA \n* SEATTLE GENETICS INC - FDA GRANTED PRIORITY REVIEW FOR APPLICATION, AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 1, 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-01-02T15:10:00.000+02:00",
    "crawled": "2018-01-02T15:23:52.065+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "genetics",
        "say",
        "fda",
        "grant",
        "hodgkin",
        "lymphoma",
        "treatment",
        "priority",
        "review",
        "status",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "seattle",
        "genetics",
        "inc",
        "fda",
        "accepts",
        "supplemental",
        "biologics",
        "license",
        "application",
        "grant",
        "priority",
        "review",
        "brentuximab",
        "vedotin",
        "frontline",
        "advanced",
        "hodgkin",
        "lymphoma",
        "seattle",
        "genetics",
        "inc",
        "fda",
        "granted",
        "priority",
        "review",
        "application",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "target",
        "action",
        "date",
        "may",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}